We initially hypothesized that clinically meaningful differences in BCR‐, MFS‐, and OS rates may exist in s‐RARP patients according to initial prostate cancer treatment with either radiation therapy or focal therapy. This evidence concerns the gene BCR and prostate carcinoma.